Diagnos Laboratorium Utama PT Tbk
PT Diagnos Laboratorium Utama Tbk provides health services using laboratories in Indonesia. The company offers clinical pathology laboratory tests comprising hematology, hemostasis, clinical chemistry, urinalysis, biomolecular, immunology, microbiology, and anatomical pathology; and genomics laboratory tests that provides genetic testing for reproductive health, pregnant women, couples who want t… Read more
Diagnos Laboratorium Utama PT Tbk - Asset Resilience Ratio
Diagnos Laboratorium Utama PT Tbk (DGNS) has an Asset Resilience Ratio of 0.32% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2024)
This chart shows how Diagnos Laboratorium Utama PT Tbk's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Diagnos Laboratorium Utama PT Tbk's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rp0.00 | 0% |
| Short-term Investments | Rp959.59 Million | 0.32% |
| Total Liquid Assets | Rp959.59 Million | 0.32% |
Asset Resilience Insights
- Limited Liquidity: Diagnos Laboratorium Utama PT Tbk maintains only 0.32% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Diagnos Laboratorium Utama PT Tbk Industry Peers by Asset Resilience Ratio
Compare Diagnos Laboratorium Utama PT Tbk's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Revvity Inc.
NYSE:RVTY |
Diagnostics & Research | 0.00% |
|
SMO ClinPlus Co. Ltd.
SHE:301257 |
Diagnostics & Research | 14.36% |
|
Berry Genomics Co Ltd
SHE:000710 |
Diagnostics & Research | 0.45% |
|
JOONGANG DNM Co.Ltd
KQ:051980 |
Diagnostics & Research | 27.26% |
|
GeneMatrix Inc
KQ:109820 |
Diagnostics & Research | 41.52% |
|
Genoray Co. Ltd
KQ:122310 |
Diagnostics & Research | 0.03% |
|
Green Cross Lab Cell Corporation
KQ:144510 |
Diagnostics & Research | 0.18% |
|
Optipharm.CO.LTD
KQ:153710 |
Diagnostics & Research | 20.73% |
Annual Asset Resilience Ratio for Diagnos Laboratorium Utama PT Tbk (2021–2024)
The table below shows the annual Asset Resilience Ratio data for Diagnos Laboratorium Utama PT Tbk.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.32% | Rp959.59 Million | Rp300.02 Billion | -0.30pp |
| 2023-12-31 | 0.62% | Rp1.70 Billion | Rp271.48 Billion | -0.44pp |
| 2022-12-31 | 1.06% | Rp2.54 Billion | Rp239.94 Billion | -1.63pp |
| 2021-12-31 | 2.69% | Rp6.51 Billion | Rp241.98 Billion | -- |